CLVT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CLVT is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock has some positive business news, but the technical trend is only neutral, analyst sentiment is mixed-to-negative with multiple target cuts, and the latest quarter showed weaker revenue and earnings despite stronger gross margin. For an impatient investor who does not want to wait for a better entry, this is still not an attractive buy today; the better call is to hold off and avoid initiating a new position here.
CLVT closed at 2.86 after a small gain from 2.79, with pre-market and post-market strength, but the broader setup remains weak. RSI_6 at 61.7 is neutral-to-slightly bullish, MACD histogram is positive but contracting, and moving averages are converging, which points to a lack of strong trend confirmation. Price is sitting near pivot 2.71 and below resistance at 2.966, with support at 2.454. The pattern-based outlook also suggests downside pressure over the next week and month, so the current technical picture does not support an aggressive long-term buy.
["Clarivate launched the Web of Science Research Intelligence platform, a potentially supportive AI-driven product catalyst.", "Q1 revenue beat expectations at nearly $586 million.", "Net income improved materially year over year according to the news summary.", "Management reaffirmed full-year revenue and adjusted EPS guidance.", "Hedge funds have been strong buyers, with buying up 182.82% over the last quarter."]
["Multiple analysts cut price targets in late February and early March.", "Barclays remains Underweight, and Citi only rates it Neutral.", "The company faces concerns about AI disintermediation risk.", "There is execution risk around the planned Life Sciences and Healthcare unit sale.", "The technical pattern suggests negative forward returns over the next day, week, and month."]
In Q1 2026, Clarivate reported revenue of $585.5 million, down 1.38% year over year. Net income and EPS were weaker in the financial snapshot, with net income at -$40.2 million and EPS at -0.06, while gross margin improved to 35.76%. The latest quarter season is Q1 2026. Overall, the company showed some margin improvement, but top-line growth and earnings quality remain soft, which is not ideal for a long-term beginner investor.
Analyst sentiment has turned more cautious recently. Citi lowered its target to $2.80 and kept Neutral, RBC cut its target to $3 and kept Sector Perform, Barclays lowered to $2.40 and kept Underweight, Goldman Sachs lowered to $3.10 and kept Neutral, while Stifel still has a Buy rating but reduced its target to $6. The Wall Street view is mixed, but the overall direction is negative because several firms are cutting targets at the same time. No recent politician or influential figure trading was reported, and there is no congress trading data available.
